For example, Brugger et al. [3] performed a large prospective biomarker study of patients with advanced non-small cell lung cancer (NSCLC) and reported that those with activating mutations of epidermal growth factor receptor (EGFR) benefit most from maintenance therapy with erlotinib. This evidence concerns the gene EGFR and non-small cell lung carcinoma.